Compare DAO & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | DMRA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2020 |
| Metric | DAO | DMRA |
|---|---|---|
| Price | $12.59 | $29.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 81.6K | ★ 801.4K |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $16.50 |
| 52 Week High | $13.04 | $30.19 |
| Indicator | DAO | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 70.50 |
| Support Level | $9.30 | $22.71 |
| Resistance Level | $12.82 | N/A |
| Average True Range (ATR) | 0.93 | 2.42 |
| MACD | 0.10 | 0.91 |
| Stochastic Oscillator | 93.42 | 98.09 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.